Literature DB >> 2731174

Modulation of O6-alkylguanine-DNA alkyltransferase in rats following intravenous administration of O6-methylguanine.

E U Dexter1, T S Yamashita, C Donovan, S L Gerson.   

Abstract

The purine analogue O6-methylguanine is an effective biochemical modulator of the DNA repair protein O6-alkylguanine-DNA alkyltransferase. Inactivation of the alkyltransferase by O6-methylguanine sensitizes tumor cells to nitrosoureas in vitro. The pharmacokinetics of O6-methylguanine were evaluated in female Sprague-Dawley rats following administration of a single 40 mg/kg i.v. bolus dose. Two-compartment pharmacokinetic analysis revealed a terminal elimination half-life of 2.3 +/- 0.68 h, a total body clearance of 6.0 +/- 0.53 ml/min/kg, and a volume of distribution at steady state of 948 +/- 186 ml/kg. To inactivate the alkyltransferase, 80 mg/kg O6-methylguanine was given at 0 and 2 h. Alkyltransferase decreased in bone marrow, kidney, lung, spleen, and intestine by 20-90%. Regeneration of alkyltransferase activity was observed 22-70 h after the first bolus dose of O6-methylguanine. A continuous infusion protocol, which achieved a steady state serum concentration of 10.3 +/- 1.5 micrograms O6-methylguanine/ml at 15 h, resulted in a similar degree of inactivation of tissue alkyltransferase to that observed following bolus drug infusion. O6-Methylguanine tissue concentrations, including that determined in brain, were 1.7- to 4-fold higher than that in serum, indicating that O6-methylguanine is concentrated in most if not all tissues. These studies establish pharmacokinetic parameters of O6-methylguanine in rats and suggest that effective biochemical modulation of alkyltransferase can be achieved in vivo. Further studies are indicated to assess the extent to which biochemical modulation of alkyltransferase reduces tumor nitrosourea resistance in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731174

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Inhibition of O6-alkylguanine-DNA alkyltransferase and DNase I activities in vitro by some alkylating substances and antineoplastic agents.

Authors:  A Link; K Tempel
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

Authors:  M E Dolan; R C Moschel; A E Pegg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

3.  Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.

Authors:  K Mineura; I Izumi; K Watanabe; M Kowada; K Kohda; M Ikenaga
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

4.  Enhancement of ACNU cytotoxicity by pretreatment with O6-methylguanine in ACNU-resistant brain tumors.

Authors:  K Mineura; I Izumi; K Watanabe; M Kowada
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice.

Authors:  V I Avramis; K K Chan; M M Solorzano; Z L Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.